IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 972
AS - Asia 936
NA - Nord America 680
SA - Sud America 266
AF - Africa 18
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.880
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 657
SG - Singapore 469
IE - Irlanda 382
BR - Brasile 226
CN - Cina 169
RU - Federazione Russa 158
IT - Italia 152
HK - Hong Kong 136
VN - Vietnam 79
SE - Svezia 71
DE - Germania 64
FI - Finlandia 46
GB - Regno Unito 28
AR - Argentina 16
TR - Turchia 14
FR - Francia 13
IN - India 13
NL - Olanda 11
BD - Bangladesh 10
CA - Canada 10
PL - Polonia 9
AT - Austria 7
EC - Ecuador 7
ID - Indonesia 7
MX - Messico 7
IQ - Iraq 6
IR - Iran 6
PK - Pakistan 6
ZA - Sudafrica 6
AU - Australia 5
BE - Belgio 5
CL - Cile 4
ES - Italia 4
JP - Giappone 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CO - Colombia 3
DZ - Algeria 3
EG - Egitto 3
MA - Marocco 3
PH - Filippine 3
PY - Paraguay 3
RO - Romania 3
SA - Arabia Saudita 3
AL - Albania 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
LT - Lituania 2
MD - Moldavia 2
UA - Ucraina 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TO - Tonga 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.880
Salva come PNG Salva come JPEG
Città #
Dublin 382
Singapore 176
Hong Kong 131
Beijing 96
Ashburn 90
Chandler 87
Nyköping 70
Santa Clara 69
Princeton 39
Helsinki 32
Ho Chi Minh City 27
Munich 27
Wilmington 25
Los Angeles 24
São Paulo 23
Dallas 20
Hanoi 16
Turku 14
Moscow 13
Assago 12
Des Moines 11
Frankfurt am Main 10
London 10
Milan 10
Naples 10
Rio de Janeiro 10
Rome 9
Seattle 9
Falkenstein 8
Kocaeli 8
New York 8
Nuremberg 8
Warsaw 8
Düsseldorf 7
Guangzhou 7
Hillsboro 7
Bari 6
Belo Horizonte 6
Curitiba 6
San Francisco 6
Ankara 5
Chicago 5
Frattamaggiore 5
Lauterbourg 5
The Dalles 5
Thái Bình 5
Brooklyn 4
Campinas 4
Cedar Knolls 4
Francavilla Fontana 4
Johannesburg 4
Long Beach 4
Ninh Bình 4
Ottawa 4
Ribeirão Preto 4
San Severo 4
Sorocaba 4
Tehran 4
Tsuen Wan 4
Ufa 4
Vienna 4
Anápolis 3
Biên Hòa 3
Brussels 3
Buenos Aires 3
Buffalo 3
Bắc Ninh 3
Caxias do Sul 3
Contagem 3
Da Nang 3
Denver 3
Guarulhos 3
Jiaxing 3
Karachi 3
Lucera 3
Mexico City 3
Norwalk 3
Phoenix 3
Porto Alegre 3
Quito 3
Reston 3
Shenzhen 3
Tokyo 3
Washington 3
Adelaide 2
Alessandria 2
Ann Arbor 2
Aparecida de Goiânia 2
Atlanta 2
Bogotá 2
Boston 2
Brasília 2
Cairo 2
Can Tho 2
Caraguatatuba 2
Casablanca 2
Catania 2
Chennai 2
Durban 2
Feira de Santana 2
Totale 1.728
Salva come PNG Salva come JPEG
Nome #
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 98
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 91
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 86
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 81
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 78
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 77
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 76
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 73
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 72
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 72
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 70
Can new chemical therapies improve the management of multiple sclerosis in children? 69
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 68
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 66
Management of dysphagia in multiple sclerosis: current best practice 64
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 63
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 62
An update on the safety of treating relapsing-remitting multiple sclerosis 62
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 61
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 57
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 56
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 56
Palliative care in progressive multiple sclerosis 52
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 51
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 50
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 50
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 49
Myeloid-derived Suppressor Cells and Multiple Sclerosis 48
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 48
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 48
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 48
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 47
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 47
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 46
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 46
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 46
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 45
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 45
Monocytic myeloid derived suppressor cells in hematological malignancies 45
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 44
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 43
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 43
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 43
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 42
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 41
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 41
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 41
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 40
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 40
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 39
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 39
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 39
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 39
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 39
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study 38
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 34
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 34
Pharmacoeconomics of synthetic therapies for multiple sclerosis 33
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 32
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 32
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series 30
New treatment targets in multiple sclerosis therapy 29
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 28
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 13
Totale 3.285
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022231 5 0 1 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024219 15 29 13 17 36 11 18 35 21 9 9 6
2024/20251.061 42 35 38 12 19 117 144 55 250 69 108 172
2025/20261.027 96 247 240 322 117 5 0 0 0 0 0 0
Totale 3.285